$6.49 14.9%
CCCC Stock Price vs. AI Score (Last 150 days)
Data gathered: July 16

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About C4 Therapeutics

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases.

C4 Therapeutics
Price $6.49
Target Price Sign up
Volume 2,590,000
Market Cap $447M
Year Range $1.18 - $11
Dividend Yield 0%
Revenue per Employee $143,781
Industry Biotechnology

In the news

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '243M10M-7.2M-28M-32M-0.410
Q4 '234.8M12M-7.3M-35M-36M-0.700
Q3 '2310M11M-82,000-27M-28M-0.520
Q2 '232.7M10M-7.6M-36M-35M-0.730
Q1 '233.6M11M-7.4M-35M-34M-0.710

Insider Transactions View All

Koppikar Utpal filed to buy 5,667 shares at $5.6.
February 10 '23
Hirsch Andrew filed to buy 10,000 shares at $8.4.
April 12 '22
Crystal Adam filed to sell 15,000 shares at $32.7.
January 5 '22
Crystal Adam filed to sell 16,054 shares at $31.6.
January 5 '22
Salter Malcolm filed to sell 10,952 shares at $30.3.
December 17 '21

What is the Market Cap of C4 Therapeutics?

The Market Cap of C4 Therapeutics is $447M.

How Many People Work at C4 Therapeutics?

As of our latest update, C4 Therapeutics employed approximately 146 people worldwide. However, it's important to note that C4 Therapeutics' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is C4 Therapeutics' revenue per employee?

$143,781. To calculate C4 Therapeutics' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of C4 Therapeutics?

Currently, the price of one share of C4 Therapeutics stock is $6.49.

How can I analyze the CCCC stock price chart for investment decisions?

The CCCC stock price chart above provides a comprehensive visual representation of C4 Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling C4 Therapeutics shares. Our platform offers an up-to-date CCCC stock price chart, along with technical data analysis and alternative data insights.

Does CCCC offer dividends to its shareholders?

As of our latest update, C4 Therapeutics (CCCC) does not offer dividends to its shareholders. Investors interested in C4 Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of C4 Therapeutics?

Some of the similar stocks of C4 Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.